nach oben

Endocrine

Erschienen in:

20.02.2018 | Editorial

Somatostatin and diabetic retinopathy: an evolving story

verfasst von: Olga Simó-Servat, Cristina Hernández, Rafael Simó

Erschienen in: Endocrine | Ausgabe 1/2018

Einloggen, um Zugang zu erhalten

Excerpt

The story of how somatostatin (SST) has come to play an evolving role in the treatment of diabetic retinopathy (DR) has to be seen in the context of the growth of scientific knowledge regarding the pathophysiology of DR. …

J.D. Poulsen, Diabetes and anterior pituitary deficiency. Diabetes 2, 7–12 (1953)CrossRefPubMed

J.D. Poulsen, Diabetes and anterior pituitary deficiency: final course and postmortem study of a diabetic patient with Sheehan’s syndrome. Diabetes 15, 73–77 (1966)CrossRefPubMed

T.J. Merimee, S.E. Fineberg, V.A. McKusik, J. Hall, Diabetes mellitus and sexual ateliotic dwarfism: comparative study. J. Clin. Invest. 49(6), 1096–1102 (1970)CrossRefPubMedPubMedCentral

P.S. Sharp, T.J. Fallon, O.J. Brazier, L. Sandler, G.F. Joplin, E.M. Kohner, Long term follow-up of patients who underwent ytrum-90 pituitary implantation for treatment of proliferative diabetic retinopathy. Diabetologia 30(4), 199–207 (1987)CrossRefPubMed

E.M. Kohner, G.F. Joplin, R.K. Black, H. Cheng, T.R. Fraser, Pituitary ablation in the treatment of diabetic retinopathy. Trans. Ophthalmol. Soc. U.K. 92, 79–90 (1972)PubMed

M.B. Grant, R.N. Mames, C. Fitzgerald, K.M. Hazariwala, R. Cooper-DeHoff, S. Caballero, K.S. Estes, The efficacy of octreotide in the therapy of severe nonproliferative and early proliferative diabetic retinopathy: a randomized controlled study. Diabetes Care 23(4), 504–509 (2000)CrossRefPubMed

B.O. Boehm, G.K. Lang, P.M. Jehle, B. Feldman, G.E. Lang, Octreotide reduces vitreous hemorrhage and loss of visual acuity risk in patients with high-risk proliferative diabetic retinopathy. Horm. Metab. Res. 33(5), 300–306 (2001)CrossRefPubMed

S.S. Palii, S. Caballero, G. Shapiro, M.B. Grant, Medical treatment of diabetic retinopathy with somatostatin analogues. Expert Opin. Investig. Drugs 16(1), 73–82 (2007)CrossRefPubMed

R. Pivonello, G. Muscogiuri, G. Holder, M. Paul, S. Sarp, A. Lesogor, P. Jordaan, J. Eisinger, A. Colao, Long-term safety of long-acting octreotide in patients with diabetic retinopathy: results of pooled data from 2 randomized, double-blind, placebo-controlled phase 3 studies. Endocrine. https://doi.org/10.1007/s12020-017-1448-5. (2017)

10.

M. Takagi, T. Babazono, Y. Uchigata, Differences in risk factors for the onset of albuminuria and decrease in glomerular filtration in people with Type 2 diabetes mellitus: implications for the pathogenesis if diabetic kidney disease. Diabet. Med. 32(10), 1354–1360 (2015)CrossRefPubMedPubMedCentral

11.

J.R. Brownrigg, C.O. Hughes, D. Burleigh, A. Karthikesalingam, B.O. Patterson, P.J. Holt, M.M. Thompson, S. de Lusignan, K.K. Ray, R.J. Hinchliffe, Microvascular disease and risk of cardiovascular events among individuals with type 2 diabetes: a population-level cohort study. Lancet Diabetes Endocrinol. 4(7), 588–597 (2016)CrossRefPubMed

12.

J.F. Payne, V. Tangpricha, J. Cleveland, M.L. Lynn, R. Ray, S.K. Srivastava, Serum insulin-like growth factor-I in diabetic retinopathy. Mol. Vis. 17, 2318–1324 (2011)PubMedPubMedCentral

13.

Q. Wang, D. Dills, R. Klein, B. Klein, S. Moss, Does insulin-like growth factor I predict incidence and progression of diabetic retinopathy? Diabetes 44(2), 161–164 (1995)CrossRefPubMed

14.

Growth Hormone Antagonist for Proliferative Diabetic Retinopathy Study Group, The effect of a growth hormone receptor antagonist drug on proliferative diabetic retinopathy. Ophthalmology 108(12), 2266–2272 (2001)CrossRef

15.

S. Azzoug, F. Chentli, Diabetic retinopathy in acromegaly. Indian J. Endocr. Metab. 18(3), 407–409 (2014)CrossRef

16.

R. Simó, E. Carrasco, M. García-Ramírez, C. Hernández, Angiogenic and antiangiogenic factors in proliferative diabetic retinopathy. Curr. Diabes. Rev. 2(1), 71–98 (2006)CrossRef

17.

C. Gerhardinger, K.D. McClure, G. Romeo, F. Podesta, M. Lorenzi, IGF-I mRNA and signaling in the diabetic retina. Diabetes 50(1), 175–183 (2001)CrossRefPubMed

18.

C. Hernández, O. Simó-Servat, R. Simó, Somatostatin and diabetic retinopathy: current concepts and new therapeutic perspectives. Endocrine 46(2), 209–214 (2014)CrossRefPubMed

19.

E. Carrasco, C. Hernández, A. Miralles, P. Huget, J. Farres, R. Simó, Lower somatostatin expression is an early event in diabetic retinopathy and is associated with retinal neurodegeneration. Diabetes Care 30(11), 2902–2908 (2007)CrossRefPubMed

20.

C. Hernández, E. Carrasco, R. Casamitjana, R. Deulofeu, J. García-Arumí, R. Simó, Somatostatin molecular variants in the vitreous fluid: a comparative study between diabetic patients with proliferative diabetic retinopathy and non-diabetic control subjects. Diabetes Care 28(8), 1941–1947 (2005)CrossRefPubMed

21.

C. Hernández, M. García-Ramírez, L. Corraliza, J. Fernández-Carneado, J. Farrera-Sinfreu, B. Ponsati, A. González-Rodríguez, A.M. Valverde, R. Simó, Topical administration of somatostatin prevents retinal neurodegeneration in experimental diabetes. Diabetes 62(7), 2569–2578 (2013)CrossRefPubMedPubMedCentral

22.

C. Hernández, P. Bogdanov, C. Solà-Adell, J. Sampedro, M. Valeri, X. Genís, O. Simó-Servat, M. García-Ramírez, R. Simó, Topical administration of DPP-IV inhibitors prevents retinal neurodegeneration in experimental diabetes. Diabetologia 60(11), 2285–2298 (2017)CrossRefPubMed

23.

C. Hernández, P. Bogdanov, L. Corraliza, M. García-Ramírez, C. Solà-Adell, J.A. Arranz, A.I. Arroba, A.M. Valverde, R. Simó, Topical administration of GLP-1 receptor agonists prevents retinal neurodegeneration in experimental diabetes. Diabetes 65(1), 172–187 (2016)PubMed

24.

A.R. Santos, L. Ribeiro, F. Bandello, R. Lattanzio, C. Egan, U. Frydkjaer-Olsen, J. García-Arumí, J. Gibson, J. Grauslund, S.P. Harding, G.E. Lang, P. Massin, E. Midena, P. Scanlon, S.J. Aldington, S. Simão, C. Schwartz, B. Ponsati, M. Porta, M.A. Costa, C. Hernández, J. Cunha-Vaz, R. Simó, European Consortium for the Early Treatment of Diabetic Retinopathy (EUROCONDOR), Functional and Structural Findings of Neurodegeneration in Early Stages of Diabetic Retinopathy: Cross-sectional Analyses of Baseline Data of the EUROCONDOR Project. Diabetes 66(9), 2503–2510 (2017)CrossRefPubMed

25.

R. Simó, F. Bandello, C. Egan, J. García-Arumí, J. Gibson, J. Grauslund, S.P. Harding, G.E. Lang, P. Massin, E. Midena, P. Scanlon, B. Ponsati, M. Porta, L. Ribeiro, C. Hernández, J. Cunha-Vaz, The European Consortium for the Early Treatment of Diabetic Retinopathy (EUROCONDOR). Topical administration of somatostatin and brimonidine in the early stages of diabetic retinopathy: results of the EUROCONDOR study. Diabetologia 60(Suppl 1), 1 (2017). https://doi.org/10.1007/s00125-017-4350-z

26.

M. Trento, O. Durando, S. Lavecchia, L. Charrier, F. Cavallo, M.A. Costa, C. Hernández, R. Simó, M. Porta, EUROCONDOR trial investigators, Vision related quality of life in patients with type 2 diabetes in the EUROCONDOR trial. Endocrine 57(1), 83–88 (2017)CrossRefPubMed

Titel: Somatostatin and diabetic retinopathy: an evolving story
verfasst von: Olga Simó-Servat
Cristina Hernández
Rafael Simó
Publikationsdatum: 20.02.2018
Verlag: Springer US
Erschienen in: Endocrine / Ausgabe 1/2018
Print ISSN: 1355-008X
Elektronische ISSN: 1559-0100
DOI: https://doi.org/10.1007/s12020-018-1561-0

Leitlinien kompakt für die Innere Medizin

Mit medbee Pocketcards sicher entscheiden.

^{Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag}

Kostenlos registrieren

Neu im Fachgebiet Innere Medizin

22.04.2024 | DGIM 2024 | Kongressbericht | Nachrichten

Update Innere Medizin

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen

Live-Webinar: Aktuelle Leitlinien bei Herz-Kreislauf-Erkrankungen

Springer Medizin

Somatostatin and diabetic retinopathy: an evolving story

Excerpt

Leitlinien kompakt für die Innere Medizin

Neu im Fachgebiet Innere Medizin

Krebspatienten impfen: Was? Wen? Und wann nicht?

Nierenultraschall: Tipps vom Profi

Bei RSV-Impfung vor 60. Lebensjahr über Off-Label-Gebrauch aufklären!

„KI sieht, was wir nicht sehen“

Update Innere Medizin

Live-Webinar: Aktuelle Leitlinien bei Herz-Kreislauf-Erkrankungen

Springer Medizin

Excerpt

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 1/2018

Female gonadal functions and ovarian reserve in patients with acromegaly: experience from a single tertiary center

Long-term safety of long-acting octreotide in patients with diabetic retinopathy: results of pooled data from 2 randomized, double-blind, placebo-controlled phase 3 studies

Relaxin activates AMPK-AKT signaling and increases glucose uptake by cultured cardiomyocytes

Reply to letter to the editor “Blood pressure variability in primary hyperparathyroidism: more data needed”

Role of structured individual patient education in the prevention of vascular complications in newly diagnosed type 2 diabetes: the INdividual Therapeutic Education in Newly Diagnosed type 2 diabetes (INTEND) randomized controlled trial

A randomized general population study of the effects of repeated health checks on incident diabetes

Leitlinien kompakt für die Innere Medizin

Neu im Fachgebiet Innere Medizin

Krebspatienten impfen: Was? Wen? Und wann nicht?

Nierenultraschall: Tipps vom Profi

Bei RSV-Impfung vor 60. Lebensjahr über Off-Label-Gebrauch aufklären!

„KI sieht, was wir nicht sehen“

Update Innere Medizin